Palisade Bio PALI 深 滬
已收盤 06-18 16:00:00 美东时间
1.87
+0.110
+6.25%
華盛通- 最 高1.93
- 今 開1.79
- 成交量 404.04万股
- 最 低 1.79
- 昨 收 1.76
- 總市值 32.46万
- 52周最高 2.855
- 市盈率 靜 --
- 換手率 2.33%
- 52周最低 0.53
- 委 比 92.76%
- 總股本 0.00亿
- 歷史最高 18405.00
- 量 比 1.36
- 振 幅 7.95%
- 歷史最低 0.53
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palisade Bio Shareholders Approve Charter Amendments, Governance Matters
Palisade Bio ( ($PALI) ) just unveiled an announcement. At its annual meeting o...
06-12 06:53
Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis Symposium
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approachDenver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI)
06-09 20:46
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include Zscaler, Brain, LG Display, Zepp Health, Globalfoundries, Posco Holdings, Insulet, Palisade Bio, Satellogic, and Box.
05-27 20:02
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio, Inc. announced that its CEO JD Finley and President & Chief Medical Officer Dr. Mitchell Jones will present at the Jefferies Global Healthcare Conference on June 2-4, 2026, in New York. The company’s presentation is scheduled for June 4, 2026, at 3:45 PM ET, and a live webcast will be available on the Events page of the Investors section of Palisade Bio’s website. Management will also participate in one-on-one meetings with qualifie...
05-27 13:00
Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 89.36 percent increase over losses of $(0.47) per share from the
05-13 04:27
Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing intervalSteady-state pharmacokinetic findings provide mechanistic support for previously
05-05 20:36
美股牛股 | 史诗级轧空行情！安飞士本月累涨近400%；Velo3D飙涨超31%！成为米其林飞行员挑战赛官方技术提供商
史诗级轧空行情！安飞士本月累涨近400%；Velo3D飙涨超31%！成为米其林飞行员挑战赛官方技术提供商；POET涨超19%，正加速面向AI的光学转型>>
04-22 15:25
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7
Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
04-10 00:38
